Full Cycle
Biotechnological Company
More than 20 years of experience in the development, production and sales of biomedical drugs
Full Cycle Biotechnological Company
More than 20 years of experience in the development, production and sales of biomedical drugs
Welcome to our website, where we are dedicated to providing comprehensive solutions for the introduction, localization, and legalization of medical drugs.
About us
General info
Mission
History
At PHARMAPARK, we understand the complexities and challenges faced by individuals and organizations in navigating the landscape of medical drugs. Our team is here to support you throughout the entire process, offering expertise and guidance to solve a wide range of tasks and issues.
We take immense pride in the quality and efficacy of our products, which are the result of rigorous research, development, and testing. Our commitment to excellence extends beyond borders, as our PHARMAPARK developments are protected by international and Russian patents. This ensures the integrity of our intellectual property and reinforces our position as a trusted and respected industry leader.
As one of the leading players in the biopharmaceutical industry in Russia, PHARMAPARK’s development strategy is centered around the creation and production of high-quality medications through biotechnology. We are committed to bringing both generic and original (brand name) medicines to the market, ensuring access to effective treatments for a wide range of health conditions.
By harnessing the power of innovation and collaboration, we serve our shareholders, investors, partners, and, most importantly, our clients, who trust in the dedication and efforts of the entire PHARMAPARK team. Together, we save lives and contribute significantly to advancing the level of healthcare in our country, enhancing the quality of life for each patient.

Every day, we strive to bring new and effective drugs to the Russian Federation market, ensuring accessibility in every city and region. Our unwavering commitment drives us forward as we work tirelessly to make a positive impact on the lives of individuals and transform the healthcare landscape in Russia.
Join us in our mission as we combine expertise, compassion, and determination to empower patients, foster medical advancements, and create a healthier future for all.
At PHARMAPARK our mission is to ensure that every individual facing debilitating diseases such as breast cancer, kidney cancer, lung cancer, colorectal cancer, hepatitis B and C, nephrology, anemia, nephroid tumors, psoriasis, rheumatoid arthritis, spondylitis, and paroxysmal nocturnal hemoglobinuria has access to the most effective and safe drugs available to combat their conditions.

We are driven by a relentless commitment to research, development, testing, and improvement, drawing upon the expertise and experience of leading global institutions and companies. Our aim is to create advanced biological drugs and cutting-edge technologies for mass production within Russia.
2023
2001
2005
2012
2016
Company was founded
2001
Launch of the production complex on area of 2,500 m2
2003
First production line (prokaryotic) is prepared for the production of the first batch
2004
Obtained GMP certificate
2005
Registered the first product (interferon substance)
2005
Launch of the second production line (eukaryotic)
2005
Start of production of the first finished dosage form (Altevir)
2006
Signing of the cooperation agreement with Center of Genetic Engineering and Biotechnology of Cuba
2011
Opening of R&D center on area of 1000 sq m
2012
First product registered (Interferon substance)
2012
Launch of an additional production plant on area of 1000 sq m
2013
Walvax cooperation agreement signed
2013
Monoclonal Antibodies production line prepared and launched
2015
Beginning of cooperation with BIO-THERA (China) on localization and registration of medical drugs: GOLIMUMAB and USTEKINUMAB
2021
Participation in the development of a scalable industrial technology for the production of the Sputnik V vaccine
2020
Cooperation agreement signed with Prestige Biopharma (South Korea)
2019
Mabxience S.A. signed an agreement on localization of Rituximab
2018
Our services
Our highly experienced team is thrilled to provide the following services
At PHARMAPARK, we offer a comprehensive range of services that encompass the full cycle of development for biological medicines.
R&D - Research and Development
Registration (Legalization)
Organization and launch of scalable serial production for various forms of medical products:
Production
Development of packaging, promotion and sale of registered drugs. Participation in tenders and public procurement.
Marketing and Sales
Pipeline
Pipeline
Product
Interferon alfa-2b
Altevir
Phase 1
Phase 2
Phase 3
Inhouse product
Hairy-cell leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, melanoma, Kaposi's sarcoma accompanied by AIDS, progressive kidney cancer.
Additional Application:
Viral hepatitis B without signs of liver cirrhosis, Viral hepatitis C without signs of liver failure.
Primary Application:
Phase 1
Phase 2
Phase 3
Peginterferon alfa-2b
Pegaltevir
Inhouse product
Chronic viral hepatitis B and C
Primary Application:
Epoetin beta
Epostim
Phase 1
Phase 2
Phase 3
Inhouse product
Chemotherapy
Additional Application:
Nephrology, anemia, nephroid tumors
Primary Application:
Filgrastim
Granogen
Phase 1
Phase 2
Phase 3
Inhouse product
Chemotherapy
Primary Application:
Epodarba
Darbopoetin alfa
Phase 1
Phase 2
Phase 3
Inhouse product
Anemia in Adult Patients with Non-Myeloid Malignancies going through chemotherapy.
Additional Application:
Anemia in adults and children with chronic renal failure
Primary Application:
Infliximab
Infliximab
Phase 1
Phase 2
Phase 3
Rheumatoid Arthritis
Primary Application:
Crohn's disease, psoriasis
Additional Application:
Inhouse product
Trastusumab
Trastusumab
Phase 1
Phase 2
Phase 3
Primary Application:
Breast Cancer
Additional Application:
Advanced adenocarcinoma of the stomach or esophagogastric junction
In cooperation with Prestige Biopharma
Adalimumab
Adalimumab
Phase 1
Phase 2
Phase 3
Inhouse product
Chronic plaque psoriasis, active purulent hidradenitis, Crohn's disease, ulcerative colitis, non-infectious uveitis, Behçet's disease
Additional Application:
Active rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis
Primary Application:
Eculisumab
Eculisumab
Phase 1
Phase 2
Phase 3
Inhouse product
Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Primary Application:
Bevatsizumab
Bevatsizumab
Phase 1
Phase 2
Phase 3
In cooperation with Prestige Biopharma
Colorectal cancer, non-squamous non-small cell lung cancer
Primary Application:
Glioblastoma, epithelial ovarian, fallopian tube and primary peritoneal cancer
Additional Application:
Ustekinumab
Ustekinumab
Phase 1
Phase 2
Phase 3
In cooperation with
Bio-Thera
Plaque psoriasis, active psoriatic arthritis
Primary Application:
Golimumab
Golimumab
Phase 1
Phase 2
Phase 3
In cooperation with
Bio-Thera
Active rheumatoid arthritis, spondylitis
Primary Application:
At PHARMAPARK, we firmly believe that our greatest resource is people - our employees, our team.
OUR TEAM
Our management team comprises seasoned professionals with a wealth of experience ranging from 10 to 25 years in the field. Their expertise and in-depth knowledge enable us to tackle any challenge in the development, production, and distribution of biological preparations and substances.

Join us on our journey as we continue to build a dynamic and talented team focused on making a meaningful impact in the biopharmaceutical industry. Together, we will drive innovation, advance healthcare, and shape a better future for all.
They are the driving force behind our success, passionately committed to achieving our goals and objectives on a daily basis. Together, we constantly evolve, develop, and grow alongside the company.
Company Management
CEO
Vyacheslav Lebedyanskiy
Executive Director
Anastasia Smirnova
R&D Director
Yuriy Seregin
Quality Director
Galina Sherbinina
Technical Director
Evgeniy Arshutkin
Сhief technologist
Margarita Aleksandrova
Logistics Director
Olga Erina
Director of Development
Pavel Grigoriev
Our Facilities
Own production facilities, warehouse complex and research center
Warehouse
R&D Center
Production Area
This facility is used for pilot and industrial production of substances. Production capacity is formed by two hardware-technological lines that are capable of creating genetically engineered therapeutic proteins, cytokines and monoclonal antibodies. The first line consists of a eukaryotic cultivation section and two protein purification sections, the second line consists of a prokaryotic cultivation section and a protein purification section.
Production lines are located at a specialized modern building with a total area of 3,600 thousand square meters.
The division carries out a full cycle of immunobiological drugs development (active pharmaceutical ingredients and finished dosage forms) based on recombinant proteins, including chemically modified ones. Development scope includes all stages of research.

The R&D Center consists of the Project Management Department, the Prokaryote Culture Laboratory, the Cell Engineering Department, the Biochemistry Laboratory, the Finished Pharmaceutical Products Development Group, the Analytical Methods Development and Transfer Department, and the Process Scaling and Validation Department.
Since 2012, research on pharmaceutical development has been carried out by the Research and Development Center
The warehouse is equipped with a modern system of storage for finished medical products and substances along with consumables, packaging material and other necessary provision, movement and shipment of it in compliance with all state standards and regulations.
PHARMAPARK’s own warehouse complex is located in close proximity to the production line.
Our Partners
With our successful experience and impeccable reputation in the biotechnology market, we offer you the opportunity to choose a reliable, predictable, and efficient partner for joint projects in the development, legalization, production, and sale of medicinal substances and drugs on the Russian market.
We are proud to showcase our trusted relationships with some of the world's leading companies
Prestige Biopharma
WALVAX Biotechnology
Bio-Thera
Mabxience S.A.
Center of Genetic Engineering and Biotechnology of Cuba
Аксель Фарм
Онко Таргет
Фарма Синтез
Фарм Стандарт
Р-Фарм
Companies cooperating with us:
Contacts
117246, Россия, Москва, Научный проезд, д.8, стр.1
Address:
Phone:
+7 (495) 411-85-94
E-mail:
info@pharmapark.ru
Fax:
+7 (495) 644-37-97
© ООО «PHARMAPARK», Russia
Информация о лекарственных препаратах, представленная на сайте, предназначена для специалистов, не должна использоваться для самостоятельной диагностики и лечения, не может служить заменой очной консультации врача.
ОГРАНИЧЕНИЕ ОТВЕТСТВЕННОСТИ
We believe in the power of collaboration and the strength that comes from working together. By partnering with PHARMAPARK, you gain access to a wealth of expertise, resources, and opportunities for growth.
Let’s get in touch.
Contacts
117246, Россия, Москва, Научный проезд, д.8, стр.1
Address:
Phone:
+7 (495) 411-85-94
E-mail:
info@pharmapark.ru
Fax:
+7 (495) 644-37-97
© ООО «PHARMAPARK», Russia
Информация о лекарственных препаратах, представленная на сайте, предназначена для специалистов, не должна использоваться для самостоятельной диагностики и лечения, не может служить заменой очной консультации врача.
ОГРАНИЧЕНИЕ ОТВЕТСТВЕННОСТИ
We believe in the power of collaboration and the strength that comes from working together. By partnering with PHARMAPARK, you gain access to a wealth of expertise, resources, and opportunities for growth.
Let’s get in touch.
Made on
Tilda